Trends in Cardiovascular Medicine
Volume 15, Issue 3 , Pages 81-85 , April 2005

PPARγ: A Critical Determinant of Body Fat Distribution in Humans and Mice

  • Yau-Sheng Tsai
    • ,
  • Nobuyo Maeda

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Nobuyo Maeda, Department of Pathology and Laboratory Medicine, University of North Carolina, 710 Brinkhous-Bullitt Bldg, Chapel Hill, NC 27599, USA. Tel.: (+1) 919-966-6914; fax: (+1) 919-966-8800.

References 

  1. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab. 2002;87:408–411
  2. Asakawa M, Takano H, Nagai T, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105:1240–1246
  3. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585–595
  4. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880–883
  5. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409–435
  6. Bluher M, Paschke R. Analysis of the relationship between PPAR-gamma 2 gene variants and severe insulin resistance in obese patients with impaired glucose tolerance. Exp Clin Endocrinol Diabetes. 2003;111:85–90
  7. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284–287
  8. Doney A, Fischer B, Frew D, et al. Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet. 2002;3:21
  9. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin–angiotensin system. Hypertension. 2000;35:1270–1277
  10. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004;10:355–361
  11. Foster DW. The lipodystrophies and other rare disorders of adipose tissue. In:  Isselbacher KJ, et al. editor. Harrison's principles of internal medicine. New York: McGraw; 1998;p. 2209–2214
  12. Friedman JM. A war on obesity, not the obese. Science. 2003;299:856–858
  13. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220–1234
  14. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453–458
  15. Gurnell M, Wentworth JM, Agostini M, et al. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem. 2000;275:5754–5759
  16. Gurnell M, Savage DB, Chatterjee VK, O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab. 2003;88:2412–2421
  17. Hamer OW, Forstner D, Ottinger I, et al. The Pro115Gln polymorphism within the PPAR gamma2 gene has no epidemiological impact on morbid obesity. Exp Clin Endocrinol Diabetes. 2002;110:230–234
  18. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA. 2003;100:15712–15717
  19. Hegele RA. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol Metab. 2003;14:371–377
  20. Hegele RA. Phenomics, lipodystrophy, and the metabolic syndrome. Trends Cardiovasc Med. 2004;14:133–137
  21. Hegele RA, Cao H, Frankowski C, et al. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 2002;51:3586–3590
  22. Kannel WB, Cupples LA, Ramaswami R, et al. Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol. 1991;44:183–190
  23. Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev. 2004;25:899–918
  24. Koutnikova H, Cock TA, Watanabe M, et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci USA. 2003;100:14457–14462
  25. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999;4:597–609
  26. Lawrence RD. Lipodystrophy and hepatomegaly with diabetes, lipemia, and other metabolic disturbances. Lancet. 1946;1:724–731
  27. Lefebvre AM, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes. 1998;47:98–103
  28. Lowell BB. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 1999;99:239–242
  29. Masugi J, Tamori Y, Mori H, et al. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000;268:178–182
  30. Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998;395:137–143
  31. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest. 2000;106:467–472
  32. Rangwala SM, Rhoades B, Shapiro JS, et al. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell. 2003;5:657–663
  33. Ristow M, Muller-Wieland D, Pfeiffer A, et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med. 1998;339:953–959
  34. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 2003;52:910–917
  35. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl. 1996;413:2–28
  36. Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S. Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes. 2002;51:718–723
  37. Terrett J, Chamberlain J, Rastan S, et al. The Pro-115→Gln mutation in peroxisome-proliferator–activated receptor (PPAR) gamma2 is extremely rare in a large cohort of US Caucasians. Clin Sci (Lond). 2000;99:89–90
  38. Tsai YS, Kim HJ, Takahashi N, et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J Clin Invest. 2004;114:240–249
  39. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341–367
  40. Zhang J, Fu M, Cui T, et al. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA. 2004;101:10703–10708

PII: S1050-1738(05)00029-0

doi: 10.1016/j.tcm.2005.04.002

Trends in Cardiovascular Medicine
Volume 15, Issue 3 , Pages 81-85 , April 2005

Article Tools

* Image Usage & Resolution